ASH 2022 | Journaal Acute Myeloïde Leukemie (AML)

In dit journaal bespreekt prof. dr. Gerwin Huls zijn selectie van het belangrijkste ASH-nieuws op het gebied van acute myeloïde leukemie. 

De volgende abstracts komen in dit journaal ter sprake: 

Plenaire sessie

• 4. In patients with relapsed/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by allo-HCT: results from the randomized phase III ASAP trial. 

Nieuwe inzichten m.b.t. intensieve chemotherapie 

• 709. Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA) as induction therapy in patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

• 710. Gimema AML1718 Part 1: planned interim analysis of a safety run-in and phase 2 open-label study of venetoclax, fludarabine, idarubicin and cytarabine (V-FLAI) in the induction therapy of non low-risk Acute myeloid leukemia

• 221. Updated phase IIb results of venetoclax with FLAG-IDA in relapsed or refractory acute myeloid leukemia 

Nieuwe inzichten in NIET intensieve therapie

• 219. Long-term follow-up of the phase 3 Viale-a clinical trial of venetoclax plus azacitidine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy

• 602. ELN Risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine

• 222. Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia

• 61. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed (ND) older/unfit or high-risk acute myeloid leukemia (AML) and relapsed/refractory (R/R) AML

• 62. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML)

• 831. Updated results from a phase I/II study of the triplet combination of azacitidine, venetoclax and gilteritinib for patients with FLT3-mutated acute myeloid leukemia

Nieuwe middelen

• 63. The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: updated results of a phase (Ph) 1 study

• 64. Update on a phase 1/2 first-in-human study of the menin-KMT2A (MLL) inhibitor ziftomenib (KO-539) in patients with relapsed or refractory acute myeloid leukemia

• 713. Use of an allogeneic leukemia-derived dendritic cell vaccine in MRD+ AML-patients results in MRD conversion, improved relapse-free survival and vaccine induced immune responses to tumor antigens

Bekijk hier het volledige overzicht van onze ASH 2022 journaals en interviews.